Jul. 6 at 6:16 PM
$ELTP $JNJ $PFE $GME
Big Pharma moving in to grab the best kept secret out of New Jersey.
Quarterly swing from loss to profit through FY 2026
Across FY 2026, Elite Pharmaceuticals moved from a basic EPS loss of US
$0.0055 in Q1, when net income excluding extra items was a loss of US
$5.9 million on US
$40.2 million of revenue, to positive basic EPS in the remaining quarters, ending Q4 with basic EPS of US
$0.0171 and net income excluding extra items of US
$18.5 million on US
$40.7 million of revenue.
